SRTS 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面獲得最高評分，但股利評分未超過2分，若公司開始配息，可能會有更優異的投資結果
SRTS 近期報酬表現
-7.63%
Sensus healthcare inc
4.57%
同產業平均
0.12%
S&P500
與 SRTS 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
GMED | Globus medical inc | 3 分 | 5 分 | 4 分 | 2 分 | 1 分 | |
NYXH | Nyxoah sa | - | 2 分 | 3 分 | - | 1 分 | |
XRAY | Dentsply sirona inc | 3 分 | 1 分 | 2 分 | 3 分 | 4 分 | |
INGN | Inogen inc | 2 分 | 5 分 | 3 分 | 1 分 | 1 分 | |
BFLY | Butterfly network inc | 3 分 | 3 分 | 2 分 | 1 分 | 1 分 |
- GMED Globus medical inc價值 3 分趨勢 5 分波段 4 分籌碼 2 分股利 1 分查看更多
SRTS 公司資訊
Sensus Healthcare, Inc. is a medical device company. The Company is focused on providing non-invasive treatments for both oncological and non-oncological skin conditions. The Company uses a low-energy X-ray technology known as superficial radiation therapy (SRT). The Company incorporated SRT into its portfolio of treatment devices: the SRT-100, SRT-100+ and SRT-100 Vision. SRT-100, is a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. Its SRT-100+ offer remote diagnostics solutions, including operation tracking.